Valo Therapeutics (Valo Tx) (Group)

https://www.valotx.com

LinkedIn: https://www.linkedin.com/company/valo-therapeutics

Valo Therapeutics (Helsinki and Oxford) is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer. *

	Start	2019-05-03 existent (s-off)
	Predecessor	University of Helsinki
	Industry	oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy)
	Industry 2	PeptiCRAd technology (Peptide-coated Conditionally Replicating Adenovirus)
	Person	Higham, Paul G. (Valo Therapeutics 202008– CEO before Glycotope + Immatics + Ark Therapeutics + GlaxoWellcome)
	Person 2	Hautsola, Matti (Valo Therapeutics 202008 Board Chairman)

	Region	Helsinki
	Country	Finland
	Street	6 Viikinkaari
	City	00790 Helsinki
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Valo Therapeutics Ltd.. (6/8/20). "Press Release: Valo Therapeutics Announces Board Appointment of Dr Mai-Britt Zocca". Oxford & Helsinki.

		Record changed: 2024-02-12